President Trump launched TrumpRx.gov at 7pm February 5 with 43 prescription drugs available at prices below retail. Cetrotide, a fertility drug, costs $301 on GoodRx and $23 on TrumpRx. The oral version of Wegovy for weight loss drops from $1,349 per month to $149. The website redirects users to manufacturer portals or provides pharmacy coupons. No government sales occur. No tax dollars fund the operation.
Five manufacturers participated at launch: AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer. Eleven additional manufacturers signed pricing deals and will add drugs in coming months. The site operates as an aggregator. Users click a drug name and either receive a coupon to present at participating pharmacies or get redirected to the manufacturer’s direct-to-consumer website. Prescriptions are still required at the pharmacy level for all prescription medications.
The weight loss drugs received prominent attention at the launch event. Wegovy pill pricing starts at $149 per month for the 1.5mg and 4mg tablets. The 4mg dose is available only until April 15, 2026, then increases to $199 per month. Injectable Wegovy drops from $1,349 per month to as low as $199. Zepbound injections fall from $1,088 to as low as $299. Ozempic, FDA-approved for diabetes but widely used for weight loss, drops from $1,028 to $350 per month average. Readers with a few extra pounds to lose might want to look at these options. The High Country Advocate does not endorse any specific medication.
Other price reductions include Zavzpret for migraines, dropping from $1,189 to $549. Fertility medications saw steep cuts, with Cetrotide falling 92 percent from its GoodRx price. Amgen’s cholesterol drug Repatha costs $239 per month on TrumpRx. Merck’s diabetes medication Januvia costs $100.
The deals are based on “Most Favored Nation” pricing. Manufacturers agreed to offer certain drugs at prices matching the lowest available in other developed countries. In exchange, companies avoided potential tariffs and gained access to a government-hosted portal directing patients to their products. Dr. Mehmet Oz, Administrator for the Centers for Medicare and Medicaid Services, told the audience, “You should not be buying drugs anymore going forward without at least checking to see if those medications are available at the discounted prices on TrumpRx.gov.”
The discounts apply only to cash-paying customers. Users must click a button stating they are not enrolled in government insurance programs like Medicare or Medicaid and will not seek insurance reimbursement for out-of-pocket costs. The site notes, “This is an out-of-pocket price. If you have insurance, check your co-pay first—it may be even lower.” Eighty-four percent of Americans have prescription drug coverage through work, individual insurance markets, or government programs like Medicare and Medicaid.
Limitations exist. TrumpRx offers only brand-name drugs. Nine out of ten prescriptions in the United States are for generic drugs, according to the FDA. Some drugs listed on TrumpRx are already available as inexpensive generics. Protonix for heartburn costs $200 on TrumpRx. The generic version, pantoprazole, costs $30 with a GoodRx coupon. For many insured patients, co-pays will be cheaper than TrumpRx cash prices, especially after meeting deductibles.
Experts interviewed by corporate media were dismissive. Rachel Sachs, a law professor who advised Biden on prescription drug policy, told the New York Times that patients “may think this is a good deal and then end up financially worse off.” Sean D. Sullivan, a health economist at the University of Washington, called TrumpRx “a side show.” The Times did not mention Sullivan’s deep involvement in progressive pharmaceutical regulation or that extending his metaphor would make Obamacare the circus.
The Financial Times reported a different perspective. Its headline stated, “Pharma stocks fall as Trump’s TrumpRx drug portal threatens revenues.” If the discounts save no money, drugmakers’ bottom lines would not be affected. GoodRx announced it is a “key integration partner” for companies offering discounts on TrumpRx, indicating the discount aggregation business sees TrumpRx as significant enough to partner with rather than compete against.
Three Senate Democrats sent a January 29 letter to the HHS Inspector General questioning whether TrumpRx complies with federal law. The lawmakers expressed concerns about illegal kickbacks, conflicts of interest, and unnecessary medication use. The letter did not specify which laws TrumpRx allegedly violates.
Trump first announced plans for the website in September 2025 when Pfizer agreed to lower prices for Medicaid drugs. The launch faced multiple delays. Dr. Oz told Trump in fall 2025 that the site would share prices before year-end. An expected late January launch was pushed back. The administration has not publicly explained the delays. Trump said the website launch is part of efforts to show his administration is addressing high costs ahead of November’s midterm elections.
The technology required to build TrumpRx is not new. Pharmaceutical companies already operate direct-to-consumer websites. Discount coupon programs like GoodRx have existed for years. TrumpRx aggregates existing manufacturer portals and coupon programs in one government-hosted location. The White House negotiated Most Favored Nation pricing deals with 16 manufacturers. The website cost no tax dollars to operate.
Democrats have promised to lower drug prices for decades. They controlled Congress in 1993-1994, 2007-2010, and 2021-2022. The FDA operates under both Democratic and Republican administrations. Testing whether manufacturers would offer lower prices for direct-to-consumer cash purchases required no legislation, no regulatory changes, no budget increase. The Trump administration asked manufacturers if they would participate. Sixteen said yes.
The website launched with 43 drugs. More will be added as additional manufacturers complete pricing agreements. Users need a prescription from a doctor, which pharmacies validate before filling orders. The site provides price transparency for brand-name drugs purchased with cash instead of insurance. Five manufacturers participated at launch. Eleven more signed deals. The federal government hosts the portal and negotiated pricing agreements. Manufacturers handle sales and fulfillment. No tax dollars fund the operation.
Support Independent Local Journalism — High Country Advocate was created as a real alternative to regional media that too often silences dissenting voices while taking sides in the political struggle. Producing in-depth, unflinching reporting like this series and others is expensive: servers, editing, research time, and legal review all add up quickly. If these articles have informed you or given you new perspective, please consider supporting HCA with a paid subscription — every subscriber helps keep this reporting strong and independent. 